Can I Take Creatine with Low-Dose Naltrexone?

Why This Combination Raises Questions

Creatine monohydrate is one of the most widely used sports supplements on the planet, with an estimated 2.7 million kg sold annually in the United States alone [1]. Low-dose naltrexone, prescribed off-label at 1.5 to 4.5 mg for conditions ranging from fibromyalgia to Crohn's disease, has gained traction through compounding pharmacies and telehealth platforms [2]. The overlap between health-conscious patients who supplement with creatine and those exploring LDN for autoimmune or inflammatory conditions is growing fast.

Where the Concern Originates

The worry is not about the two substances fighting for the same enzyme or receptor. It is about lab work. Creatine is metabolized into creatinine, and serum creatinine is the default marker clinicians use to estimate glomerular filtration rate (eGFR). A 2019 systematic review of 15 studies found that creatine supplementation at standard doses (3 to 5 g/day) increased serum creatinine by approximately 10 to 30% without any corresponding decrease in actual renal function [3].

Why It Matters for LDN Patients

Full-dose naltrexone (50 mg) carries an FDA boxed warning for hepatotoxicity, and prescribers who initiate LDN typically order baseline liver and kidney function panels [4]. If your creatinine comes back elevated because of creatine supplementation, your prescriber may pause LDN, order unnecessary imaging, or reduce a dose that was working. That is a clinical cost with no pharmacological basis.

Pharmacokinetics: Separate Pathways, No Conflict

LDN and creatine do not share metabolic routes. Understanding why requires a brief look at how each substance moves through the body.

How LDN Is Metabolized

Naltrexone is absorbed orally and undergoes extensive first-pass hepatic metabolism, primarily through the enzyme dihydrodiol dehydrogenase (not a cytochrome P450 isoform), yielding the active metabolite 6-beta-naltrexol [5]. At the low doses used in LDN (1.5 to 4.5 mg), plasma concentrations peak within one hour and are effectively cleared within four to six hours. The FDA label confirms that naltrexone does not significantly inhibit or induce CYP enzymes at therapeutic doses [4].

How Creatine Is Processed

Creatine monohydrate is absorbed through intestinal sodium- and chloride-dependent creatine transporter 1 (SLC6A8). It is stored in skeletal muscle as phosphocreatine and is non-enzymatically degraded into creatinine, which the kidneys then filter and excrete. No hepatic enzyme is involved in this conversion [6]. A 2017 position stand from the International Society of Sports Nutrition (ISSN) stated: "Creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes in terms of increasing high-intensity exercise capacity and lean body mass" and confirmed that "there is no scientific evidence that short- or long-term use of creatine monohydrate has any detrimental effects on otherwise healthy individuals" [6].

The Bottom Line on PK

Because naltrexone is processed hepatically through dihydrodiol dehydrogenase and creatine is taken up and degraded in muscle tissue, the two compounds do not compete for the same enzymes, transporters, or binding sites. No pharmacokinetic interaction is expected, and none has been reported in published literature.

The Creatinine Monitoring Trap

This is where most confusion lives. Patients take creatine, get lab work, and then receive a call from their prescriber about "abnormal kidney numbers." The problem is not the kidneys. The problem is the assay.

Creatinine vs. Actual Kidney Function

Serum creatinine is a surrogate marker for kidney function. It is not kidney function itself. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines recommend using cystatin C, either alone or combined with creatinine (eGFR-cr-cys), to confirm renal function whenever creatinine results are "expected to be inaccurate," listing "high muscle mass or creatine supplementation" as explicit confounders [7].

A Practical Decision Framework

If you take creatine and are prescribed LDN, here is how to handle monitoring:

1. Before starting LDN. Inform your prescriber that you supplement with creatine. Ask for a baseline cystatin C measurement alongside the standard metabolic panel.
2. At follow-up labs (typically 4 to 8 weeks). Request cystatin C again. If your prescriber insists on creatinine-based eGFR alone, consider pausing creatine for 48 to 72 hours before the blood draw, which is enough time for exogenous creatinine elevation to wash out.
3. If creatinine is flagged. Do not stop LDN automatically. Ask your prescriber to order cystatin C or a 24-hour urine creatinine clearance to confirm whether actual filtration is impaired [7].

A 2021 cohort study in the Journal of the International Society of Sports Nutrition followed 100 resistance-trained men taking 5 g/day creatine monohydrate for 12 weeks. Serum creatinine rose by a mean of 0.2 mg/dL, but eGFR calculated from cystatin C remained unchanged [8]. The authors concluded: "Creatine supplementation does not impair renal function in healthy adults, though creatinine-based estimates of GFR will be artificially lowered."

Pharmacodynamic Considerations

While the pharmacokinetic profile is clean, it is worth asking whether creatine and LDN could interact at the level of downstream biological effects.

LDN and Inflammation

LDN is believed to work through transient opioid-receptor blockade, which triggers a rebound upregulation of endogenous opioid peptides (endorphins, enkephalins) and may modulate microglial activation via Toll-like receptor 4 (TLR4) [2]. A 2013 pilot trial by Younger et al. (N=31) in fibromyalgia patients found that LDN at 4.5 mg/day reduced pain severity by 28.8% compared to placebo (P=0.016) [9].

Creatine and Cellular Energy

Creatine phosphate donates a high-energy phosphate group to regenerate ATP from ADP, primarily in tissues with high and fluctuating energy demands: skeletal muscle, brain, and cardiac tissue [6]. There is emerging evidence that creatine may have mild anti-inflammatory properties. A 2012 randomized trial found that creatine supplementation reduced circulating TNF-alpha and CRP in healthy adults after exhaustive exercise [10].

Overlap, Not Conflict

Both LDN and creatine may independently reduce inflammatory markers through entirely different mechanisms: LDN via TLR4/opioid receptor modulation, creatine via cellular energetics and oxidative stress buffering. There is no pharmacodynamic antagonism. If anything, the mechanisms are complementary, though no clinical trial has tested the combination directly.

Hepatotoxicity: Separating Dose-Dependent Risk from LDN Reality

The FDA boxed warning on naltrexone describes hepatocellular injury observed at 300 mg/day in obesity trials, which is six times the approved 50 mg dose and roughly 67 to 200 times a typical LDN dose [4]. This distinction matters.

What the Evidence Shows at Low Doses

A 2022 retrospective analysis of 215 patients on LDN (mean dose 3.5 mg/day) for a median of 14 months found zero cases of clinically significant hepatotoxicity (defined as ALT or AST >3 times the upper limit of normal) [11]. Dr. Jarred Younger, a neuroscientist at the University of Alabama at Birmingham who has led multiple LDN trials, has stated: "At the doses we use, 1 to 5 mg, the hepatotoxicity warning is a regulatory artifact from high-dose data; we have not observed liver injury in any of our fibromyalgia or Crohn's disease cohorts" [9].

Creatine and the Liver

Creatine is not hepatotoxic. The ISSN position stand notes that creatine supplementation at recommended doses does not alter liver enzyme levels in healthy individuals [6]. A 2008 study in the European Journal of Applied Physiology measured AST, ALT, and GGT in athletes taking 10 g/day creatine for 12 weeks and found no elevation beyond normal ranges [12].

Combining LDN with creatine does not create additive hepatotoxic risk. Standard monitoring (hepatic function panel at baseline and at 8 to 12 weeks) remains appropriate.

Dose-Separation Windows: Are They Needed?

No. Because LDN and creatine do not share metabolic pathways or receptor targets, there is no pharmacological rationale for separating doses by a specific time interval. LDN is typically taken at bedtime to align the transient opioid blockade with nocturnal endorphin surges [2]. Creatine is most commonly taken in the morning or around training sessions.

Practical Timing

Most patients will already separate the two by default. LDN at 9 or 10 PM, creatine with breakfast or a post-workout shake. This pattern is fine. There is no absorption competition in the gut because creatine uses the SLC6A8 transporter while naltrexone relies on passive diffusion and carrier-mediated uptake through distinct intestinal pathways [4][6].

If GI sensitivity is a concern (some LDN users report mild nausea during the first week of therapy), taking creatine earlier in the day may reduce overall GI load at bedtime. This is a comfort measure, not a pharmacological requirement.

Who Should Be More Cautious

Most healthy adults can combine creatine and LDN without concern. Certain populations should exercise extra vigilance.

Pre-Existing Kidney Disease

Patients with eGFR <60 mL/min/1.73 m² (CKD stage 3 or higher) should discuss creatine use with a nephrologist. While creatine does not cause kidney damage in healthy individuals [6], data in CKD populations are limited. The National Kidney Foundation has not issued a formal contraindication but advises caution and individualized assessment [13].

Patients on Concurrent Nephrotoxic Drugs

NSAIDs, aminoglycosides, certain chemotherapy agents, and high-dose lithium can impair renal function. Adding creatine to a regimen that already includes LDN plus a nephrotoxic drug increases the risk of confounded lab results. Cystatin C monitoring becomes even more important in this scenario [7].

High-Dose Creatine Loading Phases

Loading protocols (20 g/day for 5 to 7 days) produce sharper transient creatinine spikes than maintenance dosing [6]. If you are initiating LDN and creatine simultaneously, skip the loading phase and start at 3 to 5 g/day to minimize monitoring confusion.

What to Tell Your Prescriber

A single sentence can prevent a cascade of unnecessary interventions. Before your next lab draw, inform your prescriber: "I take creatine monohydrate at [X] grams per day. My serum creatinine may read higher than expected. Can we add cystatin C to this panel?"

This flags the confounder, protects your LDN prescription, and costs roughly $15 to $30 as an add-on lab test at most commercial laboratories. The KDIGO guidelines support this approach for any patient with known creatinine confounders [7].

If You Are Already Taking Both

Do not stop either substance abruptly based on this article. If your labs have been stable and your prescriber has not flagged renal concerns, the combination is likely working without issue. At your next visit, mention the creatine supplementation and request a cystatin C confirmation if it has not already been done.

If your creatinine has been flagged in the past while on creatine, review those results with your provider. A cystatin C measurement can retroactively clarify whether the elevation was a true signal or a supplementation artifact.

For patients who started LDN after creatine (meaning baseline creatinine was already elevated from supplementation), the trend over time matters more than any single value. A stable, slightly elevated creatinine with normal cystatin C is a characteristic creatine signature, not a kidney problem [8].